Novel agents in chronic lymphocytic leukemia: Efficacy and tolerability of new therapies

Clinical Lymphoma and Myeloma

Volumn 8, Issue SUPPL. 4, 2008, Pages

  Lin, Thomas S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bendamustine; Flavopiridol; Lenalidomide; Obatoclax; Oblimersen

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALLOPURINOL; ANTIDIARRHEAL AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; FLAVOPIRIDOL; FLUDARABINE; L 86 8275; LENALIDOMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; OBATOCLAX; OBLIMERSEN; PREDNISONE; PURINE DERIVATIVE; RASBURICASE; RITUXIMAB; STEROID; VINCRISTINE;

ACUTE KIDNEY FAILURE; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ATAXIA; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DIARRHEA; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; FATIGUE; GENETIC RISK; GRAM NEGATIVE SEPSIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPOTENSION; HYPOXIA; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MONOTHERAPY; MUCORMYCOSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT SAFETY; PNEUMONIA; PURPURA; RIGOR; SEPSIS; SIDE EFFECT; SOMNOLENCE; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; TUMOR FLARE; TUMOR LYSIS SYNDROME;

EID: 51049084579     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.s.009     Document Type: Conference Paper

References (30)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079-88.
2. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580-9.
3. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6.
4. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63:36-8.
5. Stilgenbauer S, Krober A, Busch R, et al. 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. Blood 2005; 106:212a (Abstract 715).
6. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554-61.
7. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103:3278-81.
8. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82:759-65.
9. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-9
10. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26:204-10.
11. Knauf WU, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. Blood 2007; 110:609a (Abstract 2043).
12. Christian BA, Fischer B, Blum KA, et al. Flavopiridol in chronic lymphocytic leukemia (CLL). Clin Leuk 2007; 1:292-7.
13. Christian BA, Grever MR, Byrd JC, et al. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2007; 19:573-8.
14. Lin TS, Howard OM, Neuberg DS, et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002; 43:793-7.
15. Flinn IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29:1253-7.
16. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005; 11:4176-81.
17. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, generically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404.
18. Lin TS, Fischer B, Blum KA, et al. Preliminary results of a phase II study of flavopiridol (Alvocidib) in relapsed chronic lymphocytic leukemia (CLL): confirmation of clinical activity in high-risk patients and achievement of complete responses (CR). Blood 2007; 110:913a (Abstract 3104).
19. Heerema NA, Byrd JC, Fischer B, et al. Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: updated data on 89 patients. Blood 2007; 110:914a (Abstract 3107).
20. Lin TS, Heerema NA, Fischer B, et al. Flavopiridol is active in genetically high-risk, relapsed chronic lymphocytic leukemia (CLL): analysis of 56 patients by cytogenetic abnormality. Blood 2006; 108:93a (Abstract 302).
21. Lin TS, Phelps MA, Dalton JT, et al. Flavopiridol can be safely dose escalated in relapsed CLL patients: achievement of target Cmax results in improved clinical activity. Blood 2006; 108:805a (Abstract 2845).
22. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-7.
23. List A, Dewald G, Bennett J, et al. Lenalidomide in the myebodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-65.
24. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:5343-9.
25. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111:5291-7.
26. Chen CI, Paul H, Mariela P, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood 2007; 110:608a (Abstract 2042).
27. Andritsos LA, Johnson AJ, Blum W, et al. Unacceptable toxicity of lenalidomide when administered to CLL patients at higher doses. J Clin Oncol 2008; 26:2519-28.
28. O'Brien S, Cunningham CC, Golenkov AK, et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23:7697-702.
29. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25:1114-20.
30. O'Brien S, Claxton D, Crump M, et al. Small molecule pan-Bcl2 family inhibitor obatoclax (GX15-070): final results of a single agent phase I trial in patients with refractory chronic lymphocytic leukemia (CLL). Haematologica 2006; 91 (suppl 1):100 (Abstract 0266).